Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 13/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.40 |
| ▸ | ERBB3 | P21860 | 13/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 13/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32425027 | 1.00 | DYRK1A (1.00) | DYRK1APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23158613 | 0.78 | DYRK1A (0.64) | DYRK1AEGFRERBB2ERBB3ERBB4 | |
| SCHEMBL1056424 | 0.74 | DYRK1A (0.59) | DYRK1AEGFRERBB2ERBB3ERBB4 | |
| SCHEMBL13186164 | 0.74 | DYRK1A (0.59) | DYRK1AEGFRERBB2ERBB3ERBB4 | |
| SCHEMBL29702869 | 0.74 | DYRK1A (0.59) | DYRK1AEGFRMKNK1MKNK2IRAK4 | |
| SCHEMBL2078428 | 0.74 | DYRK1A (0.59) | DYRK1AEGFRERBB2ERBB3ERBB4 | |
| SCHEMBL397656 | 0.74 | DYRK1A (0.59) | DYRK1AEGFRMKNK1MKNK2IRAK4 | |
| SCHEMBL3386908 | 0.74 | DYRK1A (0.59) | DYRK1AEGFRERBB2ERBB3ERBB4 | |
| Hydrochloric Acid SCHEMBL3353317 | 0.72 | DYRK1A (0.57) | DYRK1AEGFRMKNK1MKNK2IRAK4 | |
| SCHEMBL20506184 | 0.71 | DYRK1A (0.55) | DYRK1AEGFRERBB2ERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693541-A | Synthesis method of 4-chloro-5H-pyrrolo [3,2-D ] pyrimidine | 安徽大学 | 2023-09-05 | — | — | CN | claimed |
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-3891158-B1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025067468-A1 | CBL-B INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-04-03 | — | — | WO | disclosed |
| US-20250092033-A1 | HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Avistone Biotechnology Co., Ltd. (CN) | 2025-03-20 | — | — | US | disclosed |
| US-12247045-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| US-12234232-B2 | Aromatic heterocyclic compound with kinase inhibitory activity | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2025-02-25 | — | — | US | disclosed |
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240425497-A1 | Cbl-b Inhibitors and Methods of Use Thereof | ARCUS BIOSCIENCES, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| CN-1692120-A | Nucleoside phosphorylase and nucleosidase inhibitors | EINSTEIN COLL MED (US) | 2005-11-02 | — | — | CN | disclosed |
| WO-2005054247-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | SILEO, LLC | 2005-06-09 | — | — | US | disclosed |
| CN-1196704-C | Process for preparing nucleoside metabolism inhibitor and intermediate compound | IND RES LTD (NZ) | 2005-04-13 | — | — | CN | disclosed |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6693193-B1 | COUPLING AN N- AND O-PROTECTED 2,3-DIHYDROXY-PYRROLIDINE TO THE 2-POSITION AND DEPROTECTING | INDUSTRIAL RESEARCH LIMITED (NZ) | 2004-02-17 | — | — | US | disclosed |
| EP-1165564-A4 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | IND RES LTD (NZ) | 2003-01-22 | — | — | EP | disclosed |
| CN-1370171-A | Process for preparing nucleoside metabolism inhibitors | IND RES LTD (NZ) | 2002-09-18 | — | — | CN | disclosed |
| EP-1165564-A2 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | INDUSTRIAL RESEARCH LIMITED (NZ) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000061783-A2 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | INDUSTRIAL RESEARCH LIMITED (NZ) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425497-A1 | Cbl-b Inhibitors and Methods of Use Thereof | CBLB, CBL, CBLC | DYRK1A 1114/4885PDE4A 4135/4885PDE4B 3629/4885 |
| US-20250092033-A1 | HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | CYP19A1, WEE1, WEE2 | DYRK1A 3777/4885PDE4A 4725/4885PDE4B 4508/4885 |
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | DYRK1A 1266/4885PDE4A 4643/4885PDE4B 4496/4885 |
| US-12247045-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K5, MAP4K1 | DYRK1A 854/4885PDE4A 445/4885PDE4B 556/4885 |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | XDH, PNP, AGL | DYRK1A 967/4885PDE4A 3296/4885PDE4B 3165/4885 |
| US-12234232-B2 | Aromatic heterocyclic compound with kinase inhibitory activity | JAK1, JAK2, JAK3 | DYRK1A 886/4885PDE4A 2654/4885PDE4B 2185/4885 |
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | DYRK1A 1140/4885PDE4A 4081/4885PDE4B 3534/4885 |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | CD4, CCR5, PAICS | DYRK1A 4424/4885PDE4A 2114/4885PDE4B 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.